The eye study of the university of Regensburg, AugUR, deals with the causes and the development of the age-related macular degeneration (AMD). Aim is to identify new genetic and non-genetic risk factors, for improving the diagnosis, prevention and therapy of this disease. Persons over the age of 70 from Regensburg and the surrounding area are randomly chosen and invited to take part at this study.
CCCO - Comprehensive Cancer Center Ostbayern
In July 2016 the CCCO at the University Clinic of Regensburg (UKR) and Caritas Hospital St. Josef was brought to life. CCCO serves as a central coordination institution for interdisciplinary oncology healthcare provision, research and further education in the East Bavarian region.
UCC-R - University Cancer Center Regensburg
Das UCC-R ist part of the Comprehensive Cancer Centers Ostbayern (CCCO). Interdisciplinary departments work together to enable the best treatment for the patients. Beside the medical care, the medical doctors are also activ in the research of cancer medicine.
The European HIV Alliance (EHVA) is a five year project funded by the European Union's Horizon 2020 Research and Innovation Programme designed to foster the development of an effective vaccine. The EHVA encompasses 39 partners (including academic and industrial research partners from all over Europe, as well as sub-Saharan Africa and North America) , each with the expertise to promote a comprehensive approach to the development of an effective HIV vaccine. Within the alliance, the University of Regensburg coordinates the Vaccine-Discovery- Workpackage for novel antigen candidates, delivery systems and formulations.
Within ForBIMed, 11 university research groups and 9 companies work together on 11 projects. The projects mainly focus on the development of biomarker-based diagnostic tools.
Melanoma Research Network
The aim of this research network is identifying specific mechanisms of regulation of cellular signaling pathways and transcriptional control in malignant melanoma and their validation in functional models of melanoma progression. These findings will lead to new molecular therapeutic attempts to treat melanoma, which will be transferable also to other tumors.
MMML - Demonstrators
The consortium MMML-demonstrators (Molecular mechanisms in malign lymphomas demonstrators) will use these resources to design novel therapy concepts and develop diagnostic tests that accompany them. Our tests will allow physicians to pick therapies tailored to individual patients. From our mathematical models we will derive completely new therapeutic strategies.
Network OptiMD in the research network of psychical diseases
In two clinical studies and five research projects this consortium tries to improve the efficiency of antidepressants. The researcher validate suitable genetic and biochemical biomarkes, which help to measure the efficiency of already available therapies. Another research field are target structures, which influence the effect of antidepressants, for example the composition of the colon microbiom.
SYNPEPTIDE is a new FP7-sponsored project bringing together 5 academic groups and 3 SME's from across Europe to identify and use novel antibiotic molecules. It uses the methods of synthetic biology and high-throughput screening to generate and identify novel active peptides. In the preceding SYNMOD project, molecular modules have been selected and recombined to obtain enhanced and new functions and a technology for high throughput screening for antimicrobial activity has been established.